Vanhaecke A, De Schepper S, Paolino S, Heeman L, Callens H, Gutermuth J, Nguyen S, Cutolo M, Smith V (2020) Coexistence of systemic and localized scleroderma: a systematic literature review and observational cohort study. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keaa297

Article  Google Scholar 

Barnes J, Mayes MD (2012) Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 24(2):165–170. https://doi.org/10.1097/BOR.0b013e32834ff2e8

Article  PubMed  Google Scholar 

Adigun R, Goyal A, Bansal P, Hariz A (2020) Systemic Sclerosis (CREST syndrome). In: StatPearls. Treasure Island (FL)

Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, Varga J (2015) Systemic sclerosis. Nat Rev Dis Primers 1:15002. https://doi.org/10.1038/nrdp.2015.2

Article  PubMed  Google Scholar 

De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA (2013) Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 40(4):435–446. https://doi.org/10.3899/jrheum.120725

CAS  Article  PubMed  Google Scholar 

Kreuter A, Krieg T, Worm M, Wenzel J, Moinzadeh P, Kuhn A, Aberer E, Scharffetter-Kochanek K, Horneff G, Reil E, Weberschock T, Hunzelmann N (2016) German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges 14(2):199–216. https://doi.org/10.1111/ddg.12724

Article  PubMed  Google Scholar 

Mertens JS, de Jong E, van den Hoogen LL, Wienke J, Thurlings RM, Seyger MMB, Hoppenreijs E, Wijngaarde CA, van Vlijmen-Willems I, van den Bogaard E, Giovannone B, van Wijk F, van Royen-Kerkhof A, Marut W, Radstake TRD (2019) The identification of CCL18 as biomarker of disease activity in localized scleroderma. J Autoimmun 101:86–93. https://doi.org/10.1016/j.jaut.2019.04.008

CAS  Article  PubMed  Google Scholar 

Chouri E, Servaas NH, Bekker CPJ, Affandi AJ, Cossu M, Hillen MR, Angiolilli C, Mertens JS, van den Hoogen LL, Silva-Cardoso S, van der Kroef M, Vazirpanah N, Wichers CGK, Carvalheiro T, Blokland SLM, Giovannone B, Porretti L, Marut W, Vigone B, van Roon JAG, Beretta L, Rossato M, Radstake T (2018) Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. J Autoimmun 89:162–170. https://doi.org/10.1016/j.jaut.2017.12.015

CAS  Article  PubMed  Google Scholar 

Tsou PS, Sawalha AH (2017) Unfolding the pathogenesis of scleroderma through genomics and epigenomics. J Autoimmun 83:73–94. https://doi.org/10.1016/j.jaut.2017.05.004

CAS  Article  PubMed  PubMed Central  Google Scholar 

Bossini-Castillo L, Lopez-Isac E, Martin J (2015) Immunogenetics of systemic sclerosis: defining heritability, functional variants and shared-autoimmunity pathways. J Autoimmun 64:53–65. https://doi.org/10.1016/j.jaut.2015.07.005

CAS  Article  PubMed  Google Scholar 

Pearson DR, Werth VP, Pappas-Taffer L (2018) Systemic sclerosis: current concepts of skin and systemic manifestations. Clin Dermatol 36(4):459–474. https://doi.org/10.1016/j.clindermatol.2018.04.004

Article  PubMed  Google Scholar 

Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35–42. https://doi.org/10.1016/j.semarthrit.2005.03.005

CAS  Article  PubMed  Google Scholar 

Hudson M, Fritzler MJ (2014) Diagnostic criteria of systemic sclerosis. J Autoimmun 48–49:38–41. https://doi.org/10.1016/j.jaut.2013.11.004

CAS  Article  PubMed  Google Scholar 

Katsiari CG, Simopoulou T, Alexiou I, Sakkas LI (2018) Immunotherapy of systemic sclerosis. Hum Vaccin Immunother 14(11):2559–2567. https://doi.org/10.1080/21645515.2018.1491508

Article  PubMed  PubMed Central  Google Scholar 

Dellaripa PF (2018) Interstitial lung disease in the connective tissue diseases; a paradigm shift in diagnosis and treatment. Clin Immunol 186:71–73. https://doi.org/10.1016/j.clim.2017.09.015

CAS  Article  PubMed  Google Scholar 

Steen VD (2003) Scleroderma renal crisis. Rheum Dis Clin North Am 29(2):315–333. https://doi.org/10.1016/s0889-857x(03)00016-4

Article  PubMed  Google Scholar 

Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Muller-Ladner U, Coauthors E (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327–1339. https://doi.org/10.1136/annrheumdis-2016-209909

Article  PubMed  Google Scholar 

Iudici M (2017) What should clinicians know about the use of glucocorticoids in systemic sclerosis? Mod Rheumatol 27(6):919–923. https://doi.org/10.1080/14397595.2016.1270796

Article  PubMed  Google Scholar 

Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Foldvari I, Furst DE, Muller-Ladner U, Seibold J, Silver RM, Takehara K, Toth BG, Tyndall A, Valentini G, van den Hoogen F, Wigley F, Zulian F, Matucci-Cerinic M, Co-Authors E (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68(5):620–628. https://doi.org/10.1136/ard.2008.096677

CAS  Article  PubMed  Google Scholar 

Fernandez Morales A, Iniesta N, Fernandez-Codina A, Vaz de Cunha J, Perez Romero T, Hurtado Garcia R, Simeon-Aznar CP, Fonollosa V, Cervera R, Espinosa G (2017) Cardiac tamponade and severe pericardial effusion in systemic sclerosis: report of nine patients and review of the literature. Int J Rheum Dis 20(10):1582–1592. https://doi.org/10.1111/1756-185X.12952

Article  PubMed  Google Scholar 

Leng XM, Sun XF, Zhang X, Zhang W, Li MT, Zeng XF (2012) Systemic sclerosis with portal hypertensive ascites responded to corticosteroid treatment. Chin Med J (Engl) 125(13):2390–2392

Google Scholar 

Adler S, Huscher D, Siegert E, Allanore Y, Czirjak L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G, network Ec-wobotDprgwtE (2018) Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther 20(1):17. https://doi.org/10.1186/s13075-018-1517-z

CAS  Article  PubMed  PubMed Central  Google Scholar 

Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, Khanna D, Kleerup EC, Li N, Elashoff D, Elashoff RM, Scleroderma Lung Study Research G (2011) Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 63(9):2797–2808. https://doi.org/10.1002/art.30438

Article  PubMed  PubMed Central  Google Scholar 

Fernandez-Codina A, Walker KM, Pope JE, Scleroderma Algorithm G (2018) Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 70(11):1820–1828. https://doi.org/10.1002/art.40560

CAS  Article  PubMed  Google Scholar 

Mendoza FA, Lee-Ching C, Jimenez SA (2020) Recurrence of progressive skin involvement following discontinuation or dose reduction of mycophenolate mofetil treatment in patients with diffuse systemic sclerosis. Semin Arthritis Rheum 50(1):135–139. https://doi.org/10.1016/j.semarthrit.2019.06.012

CAS  Article  PubMed  Google Scholar 

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study III (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708–719. https://doi.org/10.1016/S2213-2600(16)30152-7

CAS  Article  PubMed  PubMed Central  Google Scholar 

Daoussis D, Liossis SN (2019) Treatment of systemic sclerosis associated fibrotic manifestations: current options and future directions. Mediterr J Rheumatol 30(1):33–37. https://doi.org/10.31138/mjr.30.1.33

Article  PubMed  PubMed Central  Google Scholar 

Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970. https://doi.org/10.1002/art.22204

CAS  Article  PubMed  Google Scholar 

Zheng JN, Yang QR, Zhu GQ, Pan L, Xia JX, Wang Q (2020) Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: a Bayesian network analysis. Mod Rheumatol 30(4):687–695. https://doi.org/10.1080/14397595.2019.1640343

CAS  Article  PubMed  Google Scholar 

Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirjak L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt O, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Muller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanc M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP (2017) Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis 76(7):1207–1218. https://doi.org/10.1136/annrheumdis-2016-210503

CAS  Article  PubMed  Google Scholar 

Worrell JC, O’Reilly S (2020) Bi-directional communication: conversations between fibroblasts and immune cells in systemic sclerosis. J Autoimmun 113:102526. https://doi.org/10.1016/j.jaut.2020.102526

CAS  Article  PubMed  Google Scholar 

Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled. Pilot Trial Arthritis Rheumatol 70(2):308–316. https://doi.org/10.1002/art.40358

CAS  Article  PubMed  Google Scholar 

Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellvi I, Airo P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, Lopez-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanorefor En, Y (2019) Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 78(7):979–987. https://doi.org/10.1136/annrheumdis-2018-214816

CAS  Article  PubMed  Google Scholar